Peficitinib, a JAK Inhibitor, in Combination with Limited Conventional Synthetic DMARDs in the Treatment of Moderate-to-severe Rheumatoid Arthritis
Arthritis Rheumatol DOI 10.1002/art.40054. Accepted article.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Arthritis Rheumatol DOI 10.1002/art.40054. Accepted article.
Ann Rheum Dis 2017;76:88–95.
J Am Acad Dermatol 2017;76:405–17. doi: 10.1016/j.jaad.2016.11.041
Guselkumab demonstrated superiority to adalimumab and placebo in treating PsO in this Phase 3 study. Improvements in IGA and PASI scores were observed as early as Week 16 and were maintained up to Week 48. Incidence of adverse events was similar across both treatment groups.
J Am Acad Dermatol 2017;76:418–31. doi: 10.1016/j.jaad.2016.11.042
Patients treated with guselkumab showed an improved and sustained clinical response compared to both adalimumab and placebo, without compromising safety profile. The Phase 3 VOYAGE 2 trial by Reich et al focused on treatment interruption and withdrawal, as well as treatment switching from adalimumab to guselkumab.
Arthritis Rheumatol 2016. DOI:10.1002/art.39944.
Ann Rheum Dis 2016. DOI 10.1136/annrheumdis-2016-210310
Arthritis Rheumatol 2016. DOI 10.1002/art.39953. Accepted article
Arthritis Res Ther 2016; 18:198. DOI.10.1186/s13075-016-9
Arthritis Care Res 2016; Accepted article. DOI 10.1002/acr.23004
Arthritis Care Res 2016; Accepted article. DOI 10.1002/acr.23008.